Our pipeline currently centers on two promising compounds developed by world renowned Professors’ Chang and Han.
This platform drug as shown promise for the treatment of Acute Myeloid Leukemia. Formally known as TPA, this platform small molecule has many potential therapeutic uses. Rich Pharmaceuticals is exploring multiple indications for the highest likelihood of commercialization success that has the potential to become new compelling treatments for patients.
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy